1 growth stock to consider buying at $1 that could be the next Nvidia

Attempting to find the next great growth stock may be like searching for a needle in a haystack. Still, here’s one high-risk share worth considering.

| More on:
Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After an insane 1,882% rise in five years, Nvidia has been an incredible growth stock.

I’ve been hunting for shares that could replicate this kind of performance. Here’s one potential contender — down 48% since I first invested — that I’d consider buying at $1 today.

Programmable DNA

The stock is Ginkgo Bioworks (NYSE: DNA). Since going public in 2021, it has endured a torrid time, falling around 90%.

This is a synthetic biology company that engineers cells for its customers. Its automated biofoundry is built on software, laboratory robotics and artificial intelligence (AI).

The potential applications of synthetic biology range from biodegradable plastic and lab-grown meat to drought-resistant crops and novel antibiotics.

Indeed, a start-up called Light Bio used Ginkgo’s platform to put DNA from luminous mushrooms into petunias to make them glow in the dark. I’m after buying some of these cool plants myself!

The TSMC of biology?

Essentially, the company is attempting to become in biology what Taiwan Semiconductor Manufacturing (TSMC) is to the global chip industry.

Tech firms utilise TSMC’s state-of-the-art foundries and this has enabled some to scale spectacularly.

Take Nvidia, which has become a $2.2trn company without manufacturing its own chips. Instead, it outsources this to TSMC, which itself is a $640bn colossus.

Today though, such infrastructure doesn’t really exist in healthcare. Most companies still have their own in-house labs filled with scientists running experiments. Ginkgo’s platform enables these firms to reduce R&D cycles and scale faster.

It makes money through a combination of upfront fees, milestone payments, royalties and equity. It could eventually receive around $2.4bn in potential downstream royalty payments.

Financial performance

In 2023, it added 78 new cell programmes, up from 59 in 2022. And its expects to add another 100-120 this year.

However, revenue fell 47% last year to $251m, due to declining Covid tests. And its loss from operations was a massive $864m (including stock-based compensation).

Lower losses are expected in future as it scales. Meanwhile, it finished 2023 with $944m in cash, reducing any immediate liquidity concerns.

On 10 April, the firm announced an extension of its partnership with healthcare giant Novo Nordisk for up to five years.

Such deals validate the quality of Ginkgo’s platform and many of its customers are leaders in their respective industries.

Source: Ginkgo Bioworks Q4 2023

After nearly 20 years of engineering cells, the company has accumulated mountains of biological data. It has just created a service offering this data to firms building AI models. This could juice the top line.

Looking ahead, analysts forecast strong revenue growth.



Where do I think the next amazing revolution is going to come? And this is going to be flat out one of the biggest ones ever. There’s no question that digital [synthetic] biology is going to be it.

Jensen Huang, co-founder and CEO of Nvidia

Despite its shares trading for $1, Ginkgo still has a $2.1bn market-cap. This gives the stock a price-to-sales (P/S) multiple of 8, which isn’t exactly cheap. So this is a high-risk, high-reward stock.

But if Ginkgo can reignite revenue growth and prove its AI-powered business model works, then I think it can mimic the share price growth of Nvidia in the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Ginkgo Bioworks and Taiwan Semiconductor Manufacturing. The Motley Fool UK has recommended Novo Nordisk, Nvidia, and Taiwan Semiconductor Manufacturing. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

1 superb growth stock that could be a massive winner, with help from AI

Our writer looks at one high-quality growth stock that might benefit tremendously over time from advances in artificial intelligence.

Read more »

2024 year number handwritten on a sandy beach at sunrise
Investing Articles

2 ultra-high-yield UK stocks paying me passive income

This writer highlights two high-quality FTSE 100 dividend stocks offering very lucrative passive income opportunities right now.

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Should I increase my stake in Legal & General or buy great value Aviva shares instead?

Aviva shares have had a strong year, which is bad news for Harvey Jones who bought FTSE 100 rival Legal…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

If I’d bought Lloyds shares a year ago, here’s what I’d have now

It looks like the value of my long-held Lloyds shares is moving me into profit in 2024. Are the UK's…

Read more »

Investing Articles

Here’s how I’d target a £5,900 second income by investing £50 a week

We don't need a huge pile of cash to earn a second income. Here's one way I'd aim for it…

Read more »

Grey cat peeking out from inside a cardboard box in a house
Investing Articles

Recently released: May’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’m listening to Warren Buffett and buying bargain shares!

Our writer has been taking lessons from the investing career of Warren Buffett. Here's how he's using it to try…

Read more »

Close-up of British bank notes
Investing Articles

Here’s how I’d spend £6,900 on income shares to try and earn £500 per year

Christopher Ruane outlines some of the investment principles he'd apply when trying to earn £500 of dividends annually by spending…

Read more »